Camp4 Therapeutics Files 8-K on Financials
Ticker: CAMP · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1736730
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-k
TL;DR
Camp4 Therapeutics filed an 8-K on Nov 21, 2024, detailing financial results and exhibits.
AI Summary
Camp4 Therapeutics Corp. filed an 8-K on November 21, 2024, reporting on its results of operations and financial condition. The filing provides information regarding the company's financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Cambridge, MA.
Why It Matters
This 8-K filing provides an update on Camp4 Therapeutics' financial condition and results of operations, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate or significant risks.
Key Players & Entities
- Camp4 Therapeutics Corp. (company) — Registrant
- November 21, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Cambridge, MA (location) — Address of Principal Executive Offices
- 617-651-8867 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Camp4 Therapeutics Corp.'s results of operations and financial condition, including financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on November 21, 2024.
Where are Camp4 Therapeutics Corp.'s principal executive offices located?
Camp4 Therapeutics Corp.'s principal executive offices are located at One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA 02139.
In which state is Camp4 Therapeutics Corp. incorporated?
Camp4 Therapeutics Corp. is incorporated in Delaware.
What is the registrant's telephone number as listed in the filing?
The registrant's telephone number, including area code, is (617) 651-8867.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-11-21 16:14:59
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CAMP The Nasdaq Global Ma
Filing Documents
- tm2428967d1_8k.htm (8-K) — 27KB
- tm2428967d1_ex99-1.htm (EX-99.1) — 54KB
- 0001104659-24-121533.txt ( ) — 261KB
- camp-20241121.xsd (EX-101.SCH) — 3KB
- camp-20241121_lab.xml (EX-101.LAB) — 33KB
- camp-20241121_pre.xml (EX-101.PRE) — 22KB
- tm2428967d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On November 21, 2024, CAMP4 Therapeutics Corporation issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by CAMP4 Therapeutics Corporation on November 21, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CAMP4 THERAPEUTICS CORPORATION By: /s/ Josh Mandel-Brehm Name: Josh Mandel-Brehm Title: President and Chief Executive Officer Date: November 21, 2024